Dance and walking may boost heart health in obesity — a trial puts it to the test
NCT ID NCT06127251
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This pilot trial tests whether a program of walking, dance, and abdominal core workouts can improve certain health markers in adults with obesity who are not very active. The program, called PATH, is designed to be enjoyable and stigma-free, focusing on general health benefits rather than weight loss. Researchers will measure changes in hormones like adiponectin and leptin, which are linked to inflammation and insulin sensitivity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a program of walking, dance, and abdominal core workouts
- What this could lead to
- If successful, this approach could offer a more enjoyable and sustainable way for people with obesity to improve heart health without focusing on weight loss.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The program relies on self-motivation, and long-term adherence is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Could popular Weight-Loss drugs harm your teeth? a new study investigates